<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00077194</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02571</org_study_id>
    <secondary_id>MAYO-MC0287</secondary_id>
    <secondary_id>NCI-5961</secondary_id>
    <secondary_id>CDR0000349660</secondary_id>
    <nct_id>NCT00077194</nct_id>
  </id_info>
  <brief_title>FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase II Study Of Depsipeptide, A Histone Deacetylase Inhibitor, In Relapsed Or Refractory Mantle Cell Or Diffuse Large Cell Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well FR901228 works in treating patients with relapsed or&#xD;
      refractory non-Hodgkin's lymphoma. Drugs used in chemotherapy, such as FR901228, work in&#xD;
      different ways to stop tumor cells from dividing so they stop growing or die.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the response rate (complete and partial) in patients with relapsed or refractory&#xD;
      Burkitt's, mantle cell or diffuse large cell non-Hodgkin's lymphoma treated with FR901228&#xD;
      (depsipeptide).&#xD;
&#xD;
      II. Determine the safety and feasibility of this drug, in terms of incidence and maximum&#xD;
      grade of toxicity and courses delayed or doses reduced, in these patients.&#xD;
&#xD;
      III. Determine the 2-year progression-free survival and overall survival of patients treated&#xD;
      with this drug.&#xD;
&#xD;
      IV. Correlate tumor expression of BCL-2, BCL-6, BAX, and RAS with response in patients&#xD;
      treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Treatment&#xD;
      repeats every 28 days for at least 6 courses in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months until disease progression and then every 6 months until&#xD;
      5 years from study registration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>romidepsin</intervention_name>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed aggressive B-cell non-Hodgkin's lymphoma of 1 of the&#xD;
             following cellular types:&#xD;
&#xD;
               -  Diffuse large cell&#xD;
&#xD;
               -  Mantle cell&#xD;
&#xD;
               -  Burkitt's&#xD;
&#xD;
          -  Relapsed or refractory disease&#xD;
&#xD;
               -  No more than 2 prior regimen for patients with refractory disease&#xD;
&#xD;
               -  Any number of prior therapies (including peripheral blood stem cell or bone&#xD;
                  marrow transplantation) allowed for patients with relapsed disease provided there&#xD;
                  was an objective response to the most recent therapy&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  At least 1 lesion ≥ 1.5 cm in diameter&#xD;
&#xD;
          -  No transformed lymphoma&#xD;
&#xD;
          -  No CNS lymphoma&#xD;
&#xD;
          -  Ineligible for, refused, or relapsed after stem cell transplantation&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/mm^3 (500/mm^3 in patients with extensive bone&#xD;
             marrow involvement [&gt; 50%] or hypersplenism with palpable splenomegaly)&#xD;
&#xD;
          -  Platelet count ≥ 75,000/mm^3 (50,000/mm^3 in patients with extensive bone marrow&#xD;
             involvement or hypersplenism with palpable splenomegaly)&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2 times ULN&#xD;
&#xD;
          -  AST ≤ 2 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  QTc &lt; 500 msec by ECG&#xD;
&#xD;
          -  Cardiac function ≥ 50% by MUGA&#xD;
&#xD;
          -  No prior serious ventricular arrhythmia&#xD;
&#xD;
          -  No New York Heart Association class III or IV congestive heart failure&#xD;
&#xD;
          -  No significant cardiac hypertrophy by ECG&#xD;
&#xD;
          -  No other significant cardiac disease&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No chronic obstructive pulmonary disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No diabetes&#xD;
&#xD;
          -  No other uncontrolled serious medical condition&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Prior cumulative doxorubicin dose &lt; 450 mg/m^2&#xD;
&#xD;
          -  Prior cumulative mitoxantrone dose &lt; 112 mg/m^2&#xD;
&#xD;
          -  Prior doxorubicin equivalent dose &lt; 450 mg/m^2 (for patients who have previously&#xD;
             received both doxorubicin and mitoxantrone)&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  No prior histone deacetylase inhibitor therapy&#xD;
&#xD;
          -  No concurrent medication associated with QTc prolongation, such as dolasetron&#xD;
&#xD;
          -  Concurrent hydrochlorothiazide, furosemide, or other diuretics allowed provided&#xD;
             patient is on concurrent potassium chloride supplementation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy L. Bartlett, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Washington University Siteman Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Howard University Cancer Center at Howard University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-5256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2005</verification_date>
  <study_first_submitted>February 10, 2004</study_first_submitted>
  <study_first_submitted_qc>February 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2004</study_first_posted>
  <last_update_submitted>February 8, 2013</last_update_submitted>
  <last_update_submitted_qc>February 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Romidepsin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

